REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $434.07 million. The enterprise value is $456.31 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, before market open.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 51.61 million shares outstanding. The number of shares has increased by 4.17% in one year.
| Current Share Class | 51.61M |
| Shares Outstanding | 51.61M |
| Shares Change (YoY) | +4.17% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 8.23% |
| Owned by Institutions (%) | 71.51% |
| Float | 43.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.56 |
| Forward PS | 1.71 |
| PB Ratio | 4.19 |
| P/TBV Ratio | 4.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 2.54.
| Current Ratio | 2.38 |
| Quick Ratio | 2.27 |
| Debt / Equity | 2.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.58 |
Financial Efficiency
Return on equity (ROE) is -107.00% and return on invested capital (ROIC) is -111.72%.
| Return on Equity (ROE) | -107.00% |
| Return on Assets (ROA) | -21.93% |
| Return on Invested Capital (ROIC) | -111.72% |
| Return on Capital Employed (ROCE) | -48.13% |
| Weighted Average Cost of Capital (WACC) | 11.68% |
| Revenue Per Employee | $459,410 |
| Profits Per Employee | -$522,582 |
| Employee Count | 371 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.76% in the last 52 weeks. The beta is 1.14, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -2.76% |
| 50-Day Moving Average | 10.15 |
| 200-Day Moving Average | 10.53 |
| Relative Strength Index (RSI) | 44.94 |
| Average Volume (20 Days) | 1,044,404 |
Short Selling Information
The latest short interest is 6.47 million, so 12.53% of the outstanding shares have been sold short.
| Short Interest | 6.47M |
| Short Previous Month | 6.39M |
| Short % of Shares Out | 12.53% |
| Short % of Float | 15.04% |
| Short Ratio (days to cover) | 6.78 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $170.44 million and -$193.88 million in losses. Loss per share was -$3.76.
| Revenue | 170.44M |
| Gross Profit | -78.16M |
| Operating Income | -161.20M |
| Pretax Income | -193.88M |
| Net Income | -193.88M |
| EBITDA | -145.58M |
| EBIT | -161.20M |
| Loss Per Share | -$3.76 |
Full Income StatementBalance Sheet
The company has $230.07 million in cash and $260.52 million in debt, with a net cash position of -$19.66 million or -$0.38 per share.
| Cash & Cash Equivalents | 230.07M |
| Total Debt | 260.52M |
| Net Cash | -19.66M |
| Net Cash Per Share | -$0.38 |
| Equity (Book Value) | 102.73M |
| Book Value Per Share | 2.02 |
| Working Capital | 163.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$123.96 million and capital expenditures -$2.41 million, giving a free cash flow of -$126.38 million.
| Operating Cash Flow | -123.96M |
| Capital Expenditures | -2.41M |
| Depreciation & Amortization | 15.62M |
| Net Borrowing | n/a |
| Free Cash Flow | -126.38M |
| FCF Per Share | -$2.45 |
Full Cash Flow StatementMargins
Gross margin is -45.86%, with operating and profit margins of -94.58% and -113.75%.
| Gross Margin | -45.86% |
| Operating Margin | -94.58% |
| Pretax Margin | -113.75% |
| Profit Margin | -113.75% |
| EBITDA Margin | -85.42% |
| EBIT Margin | -94.58% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.17% |
| Shareholder Yield | -4.17% |
| Earnings Yield | -44.40% |
| FCF Yield | -28.94% |
Analyst Forecast
The average price target for REGENXBIO is $28.75, which is 241.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.75 |
| Price Target Difference | 241.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 38.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -3.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.04 |
| Piotroski F-Score | 3 |
